Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 all comers meta-analysis

NIH NIAID ACTT-1, 2020
 
NCT04280705
RCTremdesevirplaceboCOVID 19 all comerssome concern
538/521 suggested
    no demonstrated benefit a
  • suggested 32 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID 19 hospitalized meta-analysis

SOLIDARITY (remdesivir), 2020
 
NCT04315948
RCTremdesevircontrolCOVID 19 hospitalizedsome concern
2750/4088 inconclusive
  • inconclusive 5 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

GS-US-540-5774, 10 days, 2020
 
NCT04292730
RCTremdesevirstandard of careCOVID-19 mild to moderatesome concern
197/200 suggested
    no demonstrated benefit a
  • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
the primary endpoint was not meet, no odds ratio is reported because theproportional odds assumption was not met
GS-US-540-5774, 5 days, 2020
 
NCT04292730
RCTremdesevirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif
    no demonstrated benefit a
  • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 53 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

CAP-China (Wang et al.), 2020
 
NCT04257656
RCTremdesevirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive
    no demonstrated benefit a
  • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);